Joseph Zabell, MD
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,910 of the $3,839 with a category attached, or 75.8%. Sanofi accounts for 62.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $2,422 and has fallen 79.4% since, to $500 in 2025.
Across 9 payments — averaging $426.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Intuitive Surgical$904
- Janssen Global Services, LLC$500
- Progenics Pharmaceuticals, Inc.$12
- Urogen Pharma, Inc.$12
Across 48 payments — averaging $11,686 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$337K
- Merck$143K
- E.r. Squibb & Sons, L.L.C.$56K
- Pfizer$25K
What the payments were for
- Consulting fees$2,91076%
- Travel & lodging$80121%
- Food & beverage$1163%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $2,410 |
| Intuitive Surgical | 5 | $904 |
| Janssen Global Services, LLC | 1 | $500 |
| Progenics Pharmaceuticals, Inc. | 1 | $12 |
| Urogen Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$2,410
- Da Vinci Surgical System$782
How this compares
$3,839 in reported general payments places this provider in the 75th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $6,769 |
| Tamsulosin Hcl | 146 | $2,317 |
| Oxybutynin Chloride ErOxybutynin Chloride | 43 | $491 |
| Finasteride | 21 | $300 |
| Levofloxacin | 38 | $210 |
| Ciprofloxacin Hcl | 107 | $204 |
| Oxybutynin Chloride | 13 | $112 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $97 |
| Cephalexin | 25 | $77 |
| Oxycodone Hcl | 19 | $31 |
Paid to pharmacies, not to this prescriber.
Other urology in Edina
- Steven BernsteinEdina$271K
- Joseph MahonEdina$86K
- Stephen OverholserEdina$20K
- Jason KemberlingEdina$19K
- Dean TortorelisEdina$19K
- Roland UgarteEdina$9K
- Paul FaddenEdina$6K
- Jeffry TwidwellEdina$6K
- Rachel MannEdina$6K
- Chase SovellEdina$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.